Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
作者:
主题词
血管生成抑制剂(Angiogenesis Inhibitors);动物(Animals);抗肿瘤药(Antineoplastic Agents);剂量效应关系, 药物(Dose-Response Relationship, Drug);女(雌)性(Female);人类(Humans);吲哚类(Indoles);最大耐受剂量(Maximum Tolerated Dose);小鼠(Mice);小鼠, 近交C57BL(Mice, Inbred C57BL);微循环(Microcirculation);卵巢肿瘤(Ovarian Neoplasms);紫杉酚(Paclitaxel);吡咯类(Pyrroles);重组蛋白质类(Recombinant Proteins);血管内皮生长因子A(Vascular Endothelial Growth Factor A)
DOI
10.1186/1479-5876-6-2
PMID
18182107
发布时间
2024-03-16
- 浏览15
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文